Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | HINT1 | P49773 | 4/20 | 0.61 |
| ▸ | NT5E | P21589 | 2/20 | 0.61 |
| ▸ | PNP | P00491 | 2/20 | 0.59 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.59 |
| ▸ | GSK3A | P49840 | 2/20 | 0.58 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.58 |
| ▸ | TGM2 | P21980 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanosine SCHEMBL12959061 | 0.94 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL5550180 | 0.94 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL973437 | 0.94 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049608 | 0.94 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL278157 | 0.94 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049467 | 0.94 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049417 | 0.94 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049416 | 0.94 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL20750695 | 0.94 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL7062800 | 0.94 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106635799-A | Screening method of guanosine production bacterial strains | 广东肇庆星湖生物科技股份有限公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-102757898-A | Method for screening guanosine high-yielding strains through membrane culture | WUHAN INST TECHNOLOGY | 2012-10-31 | — | — | CN | disclosed |
| US-7741297-B2 | Immunostimulatory, covalently lipidated oligonucleotides | ONCOTHYREON INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20060189550-A1 | Immunostimulatory, Covalently lipidated oligonucleotides | BIOMIRA INC. (CA) | 2006-08-24 | — | — | US | disclosed |
| EP-1474432-A1 | IMMUNOSTIMULATORY, COVALENTLY LIPIDATED OLIGONUCLEOTIDES | Biomira Inc. (CA) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003066649-A1 | IMMUNOSTIMULATORY, COVALENTLY LIPIDATED OLIGONUCLEOTIDES | BIOMIRA INC. (CA) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189550-A1 | Immunostimulatory, Covalently lipidated oligonucleotides | TLR9, TLR3, STING1 | HPGD 2779/4885HINT1 2450/4885NT5E 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.